Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Yong-Hong WangJuan LiaoDong-Mei ZhangDong-Bo WuYa-Chao TaoMeng-Lan WangEn-Qiang ChenHong TangPublished in: Journal of medical virology (2019)
TDF + ETV combination therapy for 48 weeks had a higher VR rate than TDF monotherapy in CHB patients with PVR to ETV.